

## Notice on the Establishment of Holding Company in China

October 20, 2020—Santen Pharmaceutical Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Shigeo Taniuchi; hereinafter, “Santen”) announced that it has established Chinese holding company in Shanghai, China.

### 1. Purpose

Santen is proceeding actively with various approaches to realize a new long-term vision looking toward 2030 and beyond. Santen considers China is an important market as it is expected to grow in many areas including glaucoma due to rapidly aging population and the availability of treatments in the future. In order to pursue investment that will contribute Santen’s sustainable growth and enhance our organizational and management capability in China with the aim of meeting the needs of this expanding market and contributing to the development of ophthalmology ecosystem in this country, Santen has established the holding company in China.

### 2. Overview of subsidiary to be newly established

(1) Name	Santen China Investment Co., Ltd.
(2) Location	Shanghai, China
(3) Representative	Chairman and Managing Director Takayuki Yamada
(4) Principal business activities	Investment of group companies in China, supervision of fund management and support of business management operations
(5) Capital	JPY 3.2 billion
(6) Date of establishment	September 24 <sup>th</sup> , 2020
(7) Major shareholders and shareholding ratio	Santen has 100% ownership

### 3. Future prospect

The impact of newly established company on this fiscal year is expected to be minor.

(Reference) Affiliated Companies in China

Name	Location	Capital	Investment ratio
Santen Pharmaceutical (China) Co., Ltd.	Suzhou, China	JPY 3.8 billion	100.0%
Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd.	Suzhou, China	CNY 35 million	100.0%
Chongqing Santen Kerui Pharmaceutical Co., Ltd.	Chongqing, China	CNY 200 million	49.0%

Contact:

Kaori Itagaki

General Manager, IR Group

E-mail: [ir@santen.com](mailto:ir@santen.com) Tel: +81-6-6321-7000

**About Santen**

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website ([www.santen.com](http://www.santen.com)).